Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
Telavancin is a bactericidal, semisynthetic lipoglycopeptide indicated in the United States for the treatment of complicated skin and skin structure infections caused by susceptible gram-positive bacteria and is under investigation as a once-daily treatment for nosocomial pneumonia. The related vanA and vanB gene clusters mediate acquired resistance to glycopeptides in enterococci by remodeling the dipeptide termini of peptidoglycan precursors from D-alanyl-D-alanine (D-Ala-D-Ala) to D-alanyl-D-lactate (D-Ala-D-Lac). In this study, we assessed the ability of telavancin to induce the expression of van genes in VanA- and VanB-type strains of vancomycin-resistant enterococci. Vancomycin, teicoplanin, and telavancin efficiently induced VanX activity in VanA-type strains, while VanX activity in VanB-type isolates was inducible by vancomycin but not by teicoplanin or telavancin. In VanA-type strains treated with vancomycin or telavancin, high levels of D-Ala-D-Lac-containing pentadepsipeptide were measured, while D-Ala-D-Ala pentapeptide was present at very low levels or not detected at all. In VanB-type strains, vancomycin but not telavancin induced high levels of pentadepsipeptide, while pentapeptide was not detected. Although vancomycin, teicoplanin, and telavancin induced similar levels of VanX activity in VanA-type strains, these organisms were more sensitive to telavancin, which displayed MIC values that were 32- and 128-fold lower than those of vancomycin and teicoplanin, respectively.
Hill
Craig M
CM
Molecular and Cellular Biology Department, Theravance, Inc., 901 Gateway Blvd., South San Francisco, CA 94080, USA. chill@theravance.com
Krause
Kevin M
KM
Lewis
Stacey R
SR
Blais
Johanne
J
Benton
Bret M
BM
Mammen
Mathai
M
Humphrey
Patrick P
PP
Kinana
Alfred
A
Janc
James W
JW
D000617:Aminoglycosides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001426:Bacterial Proteins / Q000235:genetics / Q000378:metabolism*; D015153:Blotting, Western; D019729:Carbon-Oxygen Ligases / Q000235:genetics / Q000378:metabolism*; D024881:Drug Resistance, Bacterial / Q000187:drug effects / Q000235:genetics; D016983:Enterococcus / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism*; D015964:Gene Expression Regulation, Bacterial / Q000187:drug effects / Q000235:genetics; D000077427:Lipoglycopeptides; D009876:Operon / Q000187:drug effects* / Q000235:genetics; D017334:Teicoplanin / Q000494:pharmacology; D014640:Vancomycin / Q000494:pharmacology; D020713:Vancomycin Resistance / Q000187:drug effects / Q000235:genetics
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D000077427:Lipoglycopeptides; C071437:VanA ligase, Bacteria; C079913:VanB protein, Enterococcus; D017334:Teicoplanin; D014640:Vancomycin; D019729:Carbon-Oxygen Ligases; C487637:telavancin
J Antimicrob Chemother. 2008 Jul;62(1):116-21
18424792
FEMS Microbiol Lett. 1992 Jul 1;73(1-2):195-200
1521770
Bioorg Med Chem Lett. 2000 May 15;10(10):1085-7
10843223
Clin Microbiol Rev. 2007 Jan;20(1):79-114
17223624
Antimicrob Agents Chemother. 2008 Jul;52(7):2647-52
18443122
J Bacteriol. 1996 Mar;178(5):1302-9
8631706
Mol Cell. 1998 Jul;2(1):75-84
9702193
Mol Microbiol. 1996 Jul;21(1):33-44
8843432
Antimicrob Agents Chemother. 2009 Aug;53(8):3375-83
19470513
Annu Rev Microbiol. 1984;38:339-57
6388496
J Infect Dis. 1993 May;167(5):1220-3
8486958
Biochemistry. 1991 Oct 29;30(43):10408-15
1931965
Antimicrob Agents Chemother. 1996 Oct;40(10):2291-5
8891132
J Bacteriol. 1993 Jan;175(1):117-27
8380148
Mol Gen Genet. 1986 Nov;205(2):291-7
3027505
Antimicrob Agents Chemother. 2008 Jul;52(7):2383-8
18443115
Antimicrob Agents Chemother. 2005 Mar;49(3):1127-34
15728913
J Pept Res. 2003 Aug;62(2):88-95
12823621
J Am Chem Soc. 2002 Aug 7;124(31):9064-5
12149006
J Bacteriol. 1992 Apr;174(8):2582-91
1556077
Mol Microbiol. 1994 Sep;13(6):1065-70
7854121